Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Market Closed - London S.E. Other stock markets 10:05:27 13/02/2026 pm IST			5-day change	1st Jan Change
58.00 ^GBX	-0.85%		-4.13%	-

09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Announces Executive Changes	CI

Transcript : Avacta Group Plc - Special Call

Published on 05/16/2025 at 12:20 am IST - Modified on 06/11/2025 at 09:05 am IST

S&P Capital IQ

Presenter Speech
Katie Pilbeam (Attendees)

Hello, and welcome to the Avacta webinar. This webinar is brought to you by Turner Pope, a firm that offers corporate broking services to publicly listed

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Avacta Group Plc

09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Announces Executive Changes	CI
04/02	Avacta Therapeutics Announces Two Key Clinical Updates to its Faridoxorubicin Clinical Program	CI
03/02	Avacta reports progress in faridoxorubicin clinical programme	AN
03/02	Avacta Group Updates Trial Protocol in Faridoxorubicin Program	MT
03/02	Avacta Therapeutics says cardiac dosing limit removed in Faridoxorubicin program	RE
21/01	Avacta Therapeutics Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug Application for the Second Pre\|Cision® Medicine, Fap-Exatecan	CI
21/01	EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs	AN
21/01	Avacta announces US FDA clearance of the investigational new drug application for the second pre\|CISION medicine, FAP-Exatecan	RE
21/01	Avacta Therapeutics Wins US FDA Nod to Start Early-stage Trial of Cancer Drug FAP-Exd	MT
18/12	Avacta Therapeutics Announces Faridoxorubicin Phase 1B Cohort Demonstrates Clinically Meaningful Tumor Shailage in Patients with Salivary Metals Cancer	CI
17/12	Avacta says salivary gland cancer drug shrinks tumour	AN
17/12	Avacta's Salivary Gland Cancer Therapy Shows Efficacy in Early-stage Study	MT
08/12	Avacta to announce initial phase 1b data on faridoxorubicin	AN
03/11	Avacta Therapeutics Finalizes Share Placing, Convertible Bond Amendments	MT